Advice

in the absence of a submission from the holder of the marketing authorisation:

denosumab (Prolia®) is not recommended for use within NHSScotland.

Indication under review: Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download full details212KB (PDF)

Download

Medicine details

Medicine name:
denosumab (Prolia)
SMC ID:
SMC2117
Indication:
Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
Pharmaceutical company
Amgen Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
10 September 2018